(MT Newswires) -- Novo Nordisk CEO Lars Fruergaard Jorgensen announces that the company will double its capital expenditure (CAPEX) compared to last year to meet growing demand for its weight loss medicines, including Wegovy and Ozempic. Novo Nordisk plans to invest more than €10 billion in expanding its production capacity.

In Europe, Wegovy has been launched in six countries, and the company plans to increase supply to ensure continuity of treatment. In the US, Novo Nordisk has more than doubled the number of doses since January. The company aims to serve more of the 50 million US patients eligible for its treatments.

Despite Eli Lilly's introduction of ZepBound to the US market, Jorgensen remains confident in Novo Nordisk's ability to maintain growth. He stresses the importance of competition in developing the market and serving more patients. With a valuation in excess of $500 billion, Novo Nordisk is focused on innovation and production expansion to fully exploit market opportunities.

Bloomberg videos